Andrea E. Meulen‐de Jong

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease

D. Hommes, R. Weersma, D. D. de Jong, 2017, BMJ Open.

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

D. D. de Jong, C. J. van der Woude, F. Hoentjen, 2020, Alimentary pharmacology & therapeutics.

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study

D. D. de Jong, C. J. van der Woude, F. Hoentjen, 2019, Clinical pharmacology and therapeutics.